57
Views
8
CrossRef citations to date
0
Altmetric
Letter to the Editor

Bilateral thalamic infarction after reinfusion of DMSO-preserved autologous stem-cells

, , , , &
Pages 2418-2420 | Received 17 May 2006, Accepted 02 Jun 2006, Published online: 01 Jul 2009

References

  • Davis J M, Rowley S D, Braine H G, Piantadosi S, Santos G W. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781–786
  • Ferrucci P F, Martinoni A, Cocorocchio E, Civelli M, Cinieri S, Cardinale D, et al. Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant 2000; 25: 173–177
  • Zambelli A, Poggi G, Da Prada G A, Pedrazzoli P, Cuomo A, Miotti D, et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 18: 4705–4708
  • Bauwens D, Hantson P, Laterre P F, Michaux L, Latinne D, De Tourtchaninoff M, et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leuk Lymphoma 2005; 46: 1671–1674
  • Hequet O, Dumontet C, El Jaafari-Corbin A, Salles G, Espinouse D, Arnaud P, et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant 2002; 29: 544
  • Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transplant 2000; 25: 1285–1287
  • Windrum P, Morris T CM. Severe neurotoxicity because of dimethyl sulphoxide following peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 315
  • Dhodapkar M, Goldberg S L, Tefferi A, Gertz M A. Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion. Am J Hematol 1994; 45: 187–188
  • Higman M A, Port J D, Beauchamp N R, Jr, Chen A R. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant 2000; 26: 797–800
  • Windrum P, Morris T CM, Drake M B, Niederwieser D, Ruutu T, on behalf of the EBMT Chronic Leukemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant 2005; 36: 601–603
  • Schmahmann J D. Vascular syndromes of the thalamus. Stroke 2003; 34: 2264–2278
  • Roitberg B Z, Tuccar E, Alp M S. Bilateral paramedian thalamic infarct in the presence of an unpaired thalamic perforating artery. Acta Neurochir (Wien) 2002; 144: 301–304
  • Syme R, Bewick M, Stewart D, Porter K, Chadderton T, Gluck S. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004; 10: 135–141
  • Chaloupka J C, Huddle D C, Alderman J, Fink S, Hammond R, Vinters H V. A reexamination of the angiotoxicity of superselective injection of DMSO in the swine rete embolization model. AJNR Am J Neuroradiol 1999; 20: 401–410
  • Abrahamsen J F, Bakken A M, Bruserud O. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion 2002; 42: 1573–1580

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.